U.S., March 13 -- ClinicalTrials.gov registry received information related to the study (NCT07468552) titled 'Trial of Tirzepatide for the Treatment of Cannabis Use Disorder' on March 05.
Brief Summary: The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Study Start Date: Nov. 15, 2026
Study Type: INTERVENTIONAL
Condition:
Cannabis Use Disorder
Intervention:
DRUG: Tirzepatide
Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will...